Medtronic and Biotronik both took steps forward this week with their pacemaker hardware designed to target newly emerging ...
The OmniaSecure lead gained the first U.S. approval for placement in the heart’s left bundle branch area, to help activate ...
A 173-patient randomized trial in HFrEF (LVEF ≤35%) with LBBB (QRS ≥130 ms) showed CSP was inferior to BiVP for a hierarchical 12‑month composite endpoint. Worse outcomes with CSP were reflected by an ...
The findings suggest that use of the pacing technique during CRT should be reserved for expert operators, at least for now.
Medtronic snagged FDA approval for an expanded indication for its OmniaSecure defibrillation lead. Check out why this tiny ...
Medtronic announced today that it received FDA approval for an expanded indication for its OmniaSecure defibrillation lead.
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, received U.S. Food and Drug Administration (FDA) approval for an expanded indication for the OmniaSecureâ„¢ defibrillation lead. Now ...
Please provide your email address to receive an email when new articles are posted on . Medtronic announced its cardiac lead received an expanded indication from the FDA for left bundle branch area ...
New research highlights postnatal regeneration limits and pathological remodeling of the cardiac conduction system after myocardial infarction, uncovering mechanisms behind clinical arrhythmogenesis ...
Cardiac resynchronization therapy is a key treatment for patients with HFrEF and electrical dyssynchrony, such as LBBB. While ...
NEW ORLEANS -- Among patients with heart failure, conduction system pacing-guided cardiac resynchronization therapy was associated with improvements in left ventricular ejection fraction (LVEF) ...
The TCTMD news team talks lipid guidelines, echo surveillance in AS, radiation for structural imagers, tirzepatide in TAVI, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results